Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis

PURPOSE: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). MATERIALS AND METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Junshik, Kim, Seok Jin, Ahn, Jae-Sook, Song, Moo Kon, Kim, Yu Ri, Lee, Ho Sup, Yhim, Ho-Young, Yoon, Dok Hyun, Kim, Min Kyoung, Oh, Sung Yong, Park, Yong, Mun, Yeung-Chul, Do, Young Rok, Ryoo, Hun-Mo, Lee, Je-Jung, Lee, Jae Hoon, Kim, Won Seog, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398112/
https://www.ncbi.nlm.nih.gov/pubmed/25544581
http://dx.doi.org/10.4143/crt.2014.055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398112/
https://www.ncbi.nlm.nih.gov/pubmed/25544581
http://dx.doi.org/10.4143/crt.2014.055

Ejemplares similares